Dominique HEYMANN studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He obtained successively a technician and an engineer position at the University Hospital of Nantes before to be appointed Associate-Professor in 2001 at the Department of Histology and Embryology. In 2009, He was awarded a personal Chair of Histology and Embryology. At the Nantes Hospital, he is the quality control manager of Control quality manager of the Tissue bank and Gene and Cellular Therapy Unit. At the Faculty of Medicine, he head a laboratory research group (INSERM UMR 957) of 65 people studying the pathogenesis of primary bone tumours and more specifically the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in the tumour growth. In 2006, he obtained the ‘Paul Mathieu” price of the National Academy of Medicine for the work entitled « From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma”. He participated to the national scientific advisory board of INSERM (2008-2012) and is now Vice-President of INSERM scientific commission n°5 (“Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues”). He has authored about 160 publications in peer-reviewed journals largely in the field of bone cancer and osteoclast differentiation, more than 300 abstracts, 20 book chapters and has edited in 2010 a book entitled « Bone Cancer: Progression and Therapeutic Approaches” (Publisher: Elsevier, Academic Press; second edition in preparation). He is Associate Editor of Life Sciences, academic editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.
Biography Updated on 23 June 2013